Sarepta Therapeutics reports encouraging Phase III trial data for Elevidys, its AAV-based gene therapy for Duchenne muscular dystrophy, …
Sarepta Therapeutics reports encouraging Phase III trial data for Elevidys, its AAV-based gene therapy for Duchenne muscular dystrophy, …
Evaxion Biotech reaches a key milestone in melanoma research as all patients complete dosing in its AI-driven personalized …
Generative AI has produced a novel TNIK-inhibiting compound now advancing in phase 2a trials—an unprecedented milestone in drug discovery.
CMS approval of Tempus’s AI-powered ECG‑AF algorithm marks its inclusion under U.S. Medicare reimbursement, enabling broader access to …
Late-December 2024 sees the launch of Australia’s first government-backed clinical trial using AI-guided neuromodulation to tackle severe, treatment-resistant …
December marks a turning point in computational biology, with Exscientia’s AI-designed oncology candidate advancing to mid-stage trials—reshaping how …
New CMS rules signal a turning point for AI-powered cardiac diagnostics, paving the way for broader clinical adoption …
A landmark Phase 3 clinical trial led by researchers at Mass General Brigham has demonstrated that inebilizumab, a …
Already a subscriber? Log in